News
Pharmacokinetics of Concentrates for the Treatment of von Willebrand’s Disease
Von Willebrand's disease (vWD) is characterized by a deficiency or reduced functional capacity of von Willebrand factor (vWF) and, in more severe cases, by a deficiency of coagulation factor VIII (FVIII). Treatment usually requires repeated infusions of vWF and FVIII concentrate, with available products having different factor ratios. Repeated infusions of concentrates can lead to different FVIII exposures when using different products. The pharmacokinetics of two products with varying vWF and FVIII ratios have been compared in experimental…
New Therapeutic Options in Light of Current Knowledge on the Pathogenesis of Atopic Dermatitis
Atopic dermatitis (AD) is a chronic inflammatory skin disease characterized by intense itching and…
Potential of Aloe to Reduce Severity of Symptoms in Patients with IBS − What Emerged from the Analysis of Fecal Microflora and Metabolite Profiles?
Current treatment options for irritable bowel syndrome (IBS − irritable bowel syndrome) are…
ESC 2022: SGLT2 Inhibitors as Hope for HFpEF: How to Implement Them in Practice?
Patients with heart failure (HF) can significantly benefit from the inclusion of sodium-glucose…
The Importance of Limosilactobacillus reuteri in Administration to Diabetics with Gingivitis
We summarize the results of a clinical study on the effect of probiotics containing …
Effectiveness of Compression Therapy in Patients with Leg Ulcers
Up to 2% of the population suffers from leg ulcers. The standard treatment for ulcers of venous…
Rurioctocog Alfa Pegol vs. Non-factor Therapy – Report from Real Clinical Practice
The standard treatment for hemophilia A is the prophylactic administration of coagulation factor…
Lorlatinib in a Patient with Meningeal Carcinomatosis – Case Report
The prognosis of patients with meningeal carcinomatosis is unfavorable. The following case report…
Tailored Treatment. Who is Teriflunomide Suitable For?
The authors of the recently published study cited below not only focused on the safety and efficacy…
The Future of Multiple Sclerosis – Time for a Change in Classification?
What are the latest findings on the etiopathogenesis of multiple sclerosis? Are they reflected in…